Furthermore, heightening IFNγ-R1 expression levels on tumor cells increases the susceptibility to T cell-derived IFNγ, linking transcriptional IFNγ-dependent signaling in tumors to ICB therapy response11,17,28. The gene discussed is IFNGR1; the disease is neoplasm.